Business Context and Reporting Period
This Form 8-K filing by Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) reports a corporate governance event dated May 30, 2025. The filing was signed on June 5, 2025, by Chief Executive Officer Erik Emerson.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the appointment of Erick J. Frim as Chief Financial Officer, effective May 30, 2025. Mr. Frim replaces Mark Corrao in this role.
Management Commentary and Compensation
Mr. Frim brings over 40 years of experience in financial management, including recent service as Interim CFO of Helio Corporation and as a partner at CFO Squad, LLC. He holds a CPA designation and advanced degrees from Ball State University and the University of Pennsylvania.
In connection with his appointment, the Company entered into a one-year consulting agreement dated June 4, 2025. The compensation structure includes:
- Base fee: $2,500 per month for eight hours of service.
- Overtime fee: $250 per hour for work exceeding the base allocation.
The filing states there are no reportable related party transactions or familial relationships between Mr. Frim and other Company officers or directors.
Investor Verification Checklist
- Confirm the effective date of Mark Corrao's departure and the transition timeline for the CFO role.
- Verify the total annualized cost of the new CFO consulting agreement against the company's current cash position.
- Review subsequent filings for any changes to the company's financial reporting calendar or internal controls resulting from the leadership change.